AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16442901 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks
Number of subjects: 152
Study 16442901 — intervention group
Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 152
Study 15284085 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen (0.625 mg per day)
Number of subjects: 29
Study 15284085 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (100 microg per day)
Number of subjects: 29
Study 15284085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11415918 — intervention group
Group type: EXPERIMENTAL
Intervention: 1T bismuth-coated latex shielding
Number of subjects: 30
Study 11415918 — intervention group
Group type: EXPERIMENTAL
Intervention: 2T bismuth-coated latex shielding
Number of subjects: 30
Study 11415918 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T bismuth-coated latex shielding
Number of subjects: 30
Study 11415918 — intervention group
Group type: COMPARATOR
Intervention: Control measurements (no shielding)
Number of subjects: 30
Study 9113970 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fiber-optic phototherapy
Number of subjects: 171
Study 9113970 — intervention group
Group type: EXPERIMENTAL
Intervention: Large fiber-optic phototherapy
Number of subjects: 171
Study 9113970 — intervention group
Group type: EXPERIMENTAL
Intervention: Double fiber-optic phototherapy
Number of subjects: 171
Study 9113970 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 171
Study 8214918 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% CO2 inhalation
Number of subjects: 24
Study 8214918 — intervention group
Group type: EXPERIMENTAL
Intervention: 2, 4, 6% CO2 inhalation
Number of subjects: 24
Study 8214918 — intervention group
Group type: COMPARATOR
Intervention: Control (term infants and adults)
Number of subjects: 24
Study 3512589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehousing in local authority accommodation
Number of subjects: 0
Study 3512589 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31826183 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of caffeine (CAF)
Number of subjects: 20
Study 31826183 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg of cellulose as a placebo (PLA)
Number of subjects: 20
Study 29791677 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly medical visits with provision of insulin pens and strips for blood glucose measurement, including insulin pen, refills of Neutral Protamine Hagedorn and regular insulin, needles for the pen, blood glucose meter, and capillary blood glucose tests (three tests/day) for six months.
Number of subjects: 45
Study 25490991 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined non-noxious and noxious stimulation
Number of subjects: 0
Study 25490991 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 0
Study 25490991 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious stimulation
Number of subjects: 0
Study 25490991 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-noxious stimulation
Number of subjects: 0
Study 25000665 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro XT Varnish (VXT)
Number of subjects: 31
Study 25000665 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Dentin Desensitizer (Gluma)
Number of subjects: 31
Study 25000665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (warm water)
Number of subjects: 31
Study 25000665 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between VXT and Gluma
Number of subjects: 31
Study 25000665 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between VXT and placebo
Number of subjects: 31
Study 22333849 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (4 doses of 20 mg at 1-month intervals)
Number of subjects: 21
Study 22333849 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (no medicine)
Number of subjects: 21
Study 20102447 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg silodosin
Number of subjects: 50
Study 20102447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18336918 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 0
Study 18336918 — intervention group
Group type: COMPARATOR
Intervention: Comparator (Interpersonal psychotherapy)
Number of subjects: 0
Study 18336918 — intervention group
Group type: EXPERIMENTAL
Intervention: CGT (Complicated Grief Therapy)
Number of subjects: 0
Study 15901743 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg IM ziprasidone
Number of subjects: 36
Study 15901743 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg IM ziprasidone
Number of subjects: 36
Study 15901743 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg IM ziprasidone
Number of subjects: 36
Study 15901743 — intervention group
Group type: COMPARATOR
Intervention: 5 mg IV ziprasidone
Number of subjects: 36
Study 15901743 — intervention group
Group type: COMPARATOR
Intervention: 20 mg oral ziprasidone
Number of subjects: 36
Study 11828903 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial keratotomy (RK)
Number of subjects: 96
Study 11828903 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 96
Study 10637713 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine 75 mg hs for 8 weeks
Number of subjects: 83
Study 10637713 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine 75 mg hs for 8 weeks + metronidazole 250 mg and amoxicillin 250 mg qid for 1 week on the 3rd week
Number of subjects: 83
Study 10637713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylanta (20 ml qid for 8 weeks)
Number of subjects: 83
Study 10637713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylanta (20 ml qid for 8 weeks) + metronidazole 250 mg and amoxicillin 250 mg qid for 1 week on the 3rd week
Number of subjects: 83
Study 7706829 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimony plus interferon-gamma (IFN-gamma)
Number of subjects: 31
Study 7706829 — intervention group
Group type: COMPARATOR
Intervention: Antimony alone
Number of subjects: 31
Study 2036818 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine
Number of subjects: 11
Study 2036818 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg caffeine
Number of subjects: 11
Study 2036818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7317996 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient treatment
Number of subjects: 0
Study 7317996 — intervention group
Group type: EXPERIMENTAL
Intervention: Day center treatment
Number of subjects: 0
Study 7317996 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk-in clinic treatment
Number of subjects: 0
Study 7317996 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31067997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education combined with a supplementary porridge intervention for 3 months
Number of subjects: 204
Study 28290229 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (170 units)
Number of subjects: 20
Study 28290229 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 20
Study 28290229 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (after crossover from placebo)
Number of subjects: 20
Study 28290229 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Number of subjects: 20
Study 25233911 — intervention group
Group type: EXPERIMENTAL
Intervention: Additive solution-7 (AS-7)
Number of subjects: 180
Study 25233911 — intervention group
Group type: COMPARATOR
Intervention: Control solution AS-1
Number of subjects: 180
Study 22981094 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal 2 mL 100 mg tramadol injection (group T)
Number of subjects: 52
Study 22981094 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (group P)
Number of subjects: 52
Study 22635164 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg testosterone undecanoate (intramuscular injection at weeks 0, 6, 18, 30, and 42)
Number of subjects: 120
Study 22635164 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscular injection at weeks 0, 6, 18, 30, and 42)
Number of subjects: 120
Study 19135839 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound imaging (CEUS) with a dose of 2.4 mL of a second-generation contrast agent.
Number of subjects: 84
Study 19135839 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced ultrasound imaging (US).
Number of subjects: 84
Study 17690122 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (16 puffs; 4,000 microg.day(‐1))
Number of subjects: 45
Study 17690122 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg.day(‐1))
Number of subjects: 45
Study 17690122 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo for fluticasone)
Number of subjects: 45
Study 17690122 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo for prednisone)
Number of subjects: 45
Study 16212139 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate at 5 mg/d
Number of subjects: 2483
Study 16212139 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate at 15 mg/d
Number of subjects: 2483
Study 16212139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2483
Study 16212139 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate at 35 mg once weekly
Number of subjects: 2483
Study 16212139 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate at 50 mg once weekly
Number of subjects: 2483
Study 11847044 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography
Number of subjects: 120
Study 11045061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S, n = 20)
Number of subjects: 40
Study 11045061 — intervention group
Group type: COMPARATOR
Intervention: Halothane (group H, n = 20)
Number of subjects: 40
Study 7673013 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy
Number of subjects: 54
Study 1981318 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12
Study 1981318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol
Number of subjects: 12
Study 1981318 — intervention group
Group type: COMPARATOR
Intervention: Atenolol and Bopindolol
Number of subjects: 12
Study 1981318 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 12
Study 7025315 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal gastric exclusion (bypass)
Number of subjects: 100
Study 7025315 — intervention group
Group type: COMPARATOR
Intervention: Modified Gomez gastric partitioning
Number of subjects: 100
Study 28221821 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry supplementation for 16 weeks
Number of subjects: 0
Study 28221821 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 27496698 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal mood at baseline measured with the Beck Anxiety Inventory
Number of subjects: 111
Study 27496698 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological resource factors (pain self‐efficacy)
Number of subjects: 111
Study 27496698 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological resource factors (satisfaction with life)
Number of subjects: 111
Study 27496698 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 111
Study 27496698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of movement (kinesiophobia)
Number of subjects: 111
Study 24937270 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation with random frequency (1-5 Hz)
Number of subjects: 38
Study 24937270 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 38
Study 24937270 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation with 1 Hz
Number of subjects: 38
Study 24937270 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation with 100 Hz
Number of subjects: 38
Study 22089476 — intervention group
Group type: EXPERIMENTAL
Intervention: ITL10 (10 cm H2O)
Number of subjects: 8
Study 22089476 — intervention group
Group type: EXPERIMENTAL
Intervention: ITL15 (15 cm H2O)
Number of subjects: 8
Study 22089476 — intervention group
Group type: EXPERIMENTAL
Intervention: ITL20 (20 cm H2O)
Number of subjects: 8
Study 22089476 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 8
Study 20413077 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Choices motivational intervention (4 sessions)
Number of subjects: 186
Study 20413077 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Choices motivational intervention (at least 2 sessions)
Number of subjects: 186
Study 20413077 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary specialty care alone (control)
Number of subjects: 186
Study 19093930 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare Part D coverage for clopidogrel, proton pump inhibitors (PPIs), warfarin, and statins
Number of subjects: 13032
Study 19093930 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines (not covered through Part D)
Number of subjects: 13032
Study 19093930 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare Part D coverage for PPIs
Number of subjects: 13032
Study 19093930 — intervention group
Group type: EXPERIMENTAL
Intervention: Other study drug classes (warfarin, statins, benzodiazepines)
Number of subjects: 13032
Study 16928933 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention balloon catheter
Number of subjects: 223
Study 16928933 — intervention group
Group type: COMPARATOR
Intervention: Standard tip catheter
Number of subjects: 223
Study 14641666 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid modified resin composites (F‐2000, Hytac, Compoglass F)
Number of subjects: 30
Study 14641666 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement (Fuji II LC)
Number of subjects: 30
Study 14641666 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer (Ketac‐Fil)
Number of subjects: 30
Study 14641666 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite (Z‐100)
Number of subjects: 30
Study 10823442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg orally 1 hour before barium suspension
Number of subjects: 45
Study 10823442 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 20 mg orally 1 hour before barium suspension
Number of subjects: 45
Study 8542002 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000 IU oral)
Number of subjects: 32
Study 8542002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1838046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature at 33 degrees C
Number of subjects: 32
Study 7065387 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemonetics cell saver
Number of subjects: 20
Study 7065387 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-transfusion of washed packed red cells
Number of subjects: 20
Study 31550080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal grafts and pedicled flap reconstruction of the neo‐ostium
Number of subjects: 50
Study 31550080 — intervention group
Group type: COMPARATOR
Intervention: No mucosal grafts and pedicled flap reconstruction
Number of subjects: 50
Study 28927475 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Precautions (CP)
Number of subjects: 3154
Study 28927475 — intervention group
Group type: COMPARATOR
Intervention: Standard Precautions (SP)
Number of subjects: 3154
Study 25486299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity stretching intervention (8 weeks, average of 3.1 sessions per week)
Number of subjects: 10
Study 25486299 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 10
Study 23510792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (600 ?g)
Number of subjects: 218
Study 23510792 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion (20 intravenous units)
Number of subjects: 218
Study 23510792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 218
Study 21550561 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 21550561 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 19142086 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta sleep-inducing peptide (DSIP) at 25 nmol kg(‐1)
Number of subjects: 24
Study 19142086 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta sleep-inducing peptide (DSIP) at 50 nmol kg(‐1)
Number of subjects: 24
Study 19142086 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta sleep-inducing peptide (DSIP) at 100 nmol kg(‐1)
Number of subjects: 24
Study 19142086 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 16937072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) during pregnancy, three sessions between week 23 and 30 and one session 6 weeks after delivery, combined with written information
Number of subjects: 264
Study 16937072 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 264
Study 15218330 — intervention group
Group type: EXPERIMENTAL
Intervention: benidipine (4-8 mg/day)
Number of subjects: 10
Study 15218330 — intervention group
Group type: COMPARATOR
Intervention: nifedipine CR (20-40 mg/day)
Number of subjects: 10
Study 11523124 — intervention group
Group type: COMPARATOR
Intervention: Method 1 (conventional procedure): oral magnesium citrate followed by glycerin enema.
Number of subjects: 38
Study 11523124 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2 (new procedure): oral magnesium citrate followed by oral picosulfate and bisacodyl suppository.
Number of subjects: 38
Study 9748048 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (300 to 2,400 mg/d)
Number of subjects: 4
Study 9748048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 7820984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clarithromycin infusion (1.5 mg/kg)
Number of subjects: 0
Study 7820984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3273863 — intervention group
Group type: EXPERIMENTAL
Intervention: One antacid tablet (experimental)
Number of subjects: 15
Study 3273863 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml of liquid antacid (commercial)
Number of subjects: 15
Study 3273863 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of liquid antacid (commercial)
Number of subjects: 15
Study 3273863 — intervention group
Group type: EXPERIMENTAL
Intervention: Two antacid tablets (experimental)
Number of subjects: 15
Study 3273863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31010090 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support (Reassurance of Worth and Reliable Alliance)
Number of subjects: 54
Study 31010090 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal depression
Number of subjects: 54
Study 26960538 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol at the recommended dose (0.11 mmol/kg body weight)
Number of subjects: 23708
Study 26960538 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol at the recommended dose
Number of subjects: 23708
Study 25775052 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin with a post-PCI infusion (n=735)
Number of subjects: 2194
Study 25775052 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (n=729)
Number of subjects: 2194
Study 25775052 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus tirofiban (n=730)
Number of subjects: 2194
Study 25775052 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 2194
Study 25775052 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 2194
Study 25775052 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus tirofiban
Number of subjects: 2194
Study 23578440 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐O‐T+FIT (N‐O‐T plus a physical activity module)
Number of subjects: 233
Study 23578440 — intervention group
Group type: COMPARATOR
Intervention: Not‐On‐Tobacco (N‐O‐T, teen cessation program)
Number of subjects: 233
Study 23578440 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention (standard of care)
Number of subjects: 233
Study 21558571 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Reduction (SR) - 0.7% weekly weight loss
Number of subjects: 24
Study 21558571 — intervention group
Group type: COMPARATOR
Intervention: Fast Reduction (FR) - 1.4% weekly weight loss
Number of subjects: 24
Study 21558571 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SR and FR
Number of subjects: 24
Study 19838787 — intervention group
Group type: EXPERIMENTAL
Intervention: self-help-based communal living setting (Oxford House)
Number of subjects: 150
Study 19838787 — intervention group
Group type: COMPARATOR
Intervention: usual aftercare
Number of subjects: 150
Study 16749571 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 90
Study 16749571 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 90
Study 16749571 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 90
Study 15648293 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (specific regimens not detailed)
Number of subjects: 0
Study 15648293 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with radiotherapy (specific regimens not detailed)
Number of subjects: 0
Study 15648293 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant therapy
Number of subjects: 0
Study 11866203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate and experienced observers
Number of subjects: 59
Study 11866203 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed instructions
Number of subjects: 59
Study 11866203 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative modeled behaviors
Number of subjects: 59
Study 11866203 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviors with shown consequences
Number of subjects: 59